【摘要】 目的:探讨谷胱甘肽S转移酶-π(GST-π)、DNA拓扑异构酶-Ⅱ(TOPO-Ⅱ)在非小细胞肺癌(NSCLC)化疗前的表达及其临床意义。方法:采用免疫组化双染色法检测97例肺癌组织及21例癌旁组织中GST-π、TOPO-Ⅱ的表达水平。结果:肺癌组织中GST-π、TOPO-Ⅱ的阳性表达率分别为64.95%、60.83%,其表达与性别、年龄、TNM分期及淋巴结转移无显著相关性(P>0.05)。GST-π的阳性表达率则随着分化程度的降低而降低,而TOPO-Ⅱ的阳性表达率随着分化程度的降低而升高,两者的阳性表达率在高分化与低分化组间均有显著性差异(P<0.05)。GST-π的阳性表达率与组织类型无关,而TOPO-Ⅱ的阳性表达率在鳞状细胞癌中明显高于腺癌(P<0.05)。结论:在NSCLC中存在原发耐药。联合检测化疗前NSCLC中耐药蛋白GST-π、TOPO-Ⅱ的表达,为临床治疗方案的选择提供有益的信息。更多还原

【Abstract】 Objective:To investigate the expression and its clinical significance of glutathione transferase-π(GST-π),DNA topoisomerase-Ⅱ(TOPO-Ⅱ) in non small-cell lung cancer(NSCLC) before chemotherapy. Methods:Immunohistochemistry double color technique was used to evaluated the expression of GST-π,TOPO-Ⅱin cancer tissues of 97 cases of NSCLC and 21 cases of paracancerous tissues.Results:The positive rates of GST-π,TOPO-Ⅱin NSCLC were 64.95%,60.83%,which were not correlated with sex,age,TNM stage and lymph node metastasis(P>0.05);The positive rate of GST-π was decreased with lowerly differentiated carcinomas,but the positive rate of TOPO-Ⅱwas increased with lowerly differentiated carcinomas,both the positive rates were significantly different between highly and lowly differentiated carcinomas(P<0.05);The positive rate of GST-π was not correlated with histological types,but the positive rate of TOPO-Ⅱwas significantly higher in squamous cell carcinoma than that in adenocarcinoma (P<0.05).Conclusion:Primary drug resistance exists in NSCLC.To examine the expression of GST-π,TOPO-Ⅱtogether before chemotherapy in NSCLC can offer beneficial information for the choice of the clinical therapeutic ways.更多还原